Inovalon (INOV) Receiving Somewhat Negative Press Coverage, Study Finds

News articles about Inovalon (NASDAQ:INOV) have been trending somewhat negative recently, according to Accern. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Inovalon earned a news sentiment score of -0.03 on Accern’s scale. Accern also assigned news headlines about the technology company an impact score of 46.9057349912702 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have impacted Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

INOV stock traded down $0.20 during trading on Friday, hitting $10.30. The stock had a trading volume of 758,867 shares, compared to its average volume of 703,459. Inovalon has a 1-year low of $10.10 and a 1-year high of $17.80. The company has a market capitalization of $1,516.22, a price-to-earnings ratio of 44.78, a PEG ratio of 2.94 and a beta of 1.03. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.32.

Inovalon (NASDAQ:INOV) last announced its earnings results on Tuesday, February 20th. The technology company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.01). The firm had revenue of $114.60 million during the quarter, compared to analyst estimates of $116.83 million. Inovalon had a net margin of 7.51% and a return on equity of 4.79%. The company’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.05 EPS. research analysts predict that Inovalon will post 0.25 earnings per share for the current year.

A number of equities analysts have recently issued reports on INOV shares. BidaskClub lowered shares of Inovalon from a “sell” rating to a “strong sell” rating in a research report on Thursday, December 14th. Morgan Stanley downgraded Inovalon from an “equal weight” rating to an “underweight” rating and set a $10.00 target price for the company. in a report on Wednesday, March 14th. Zacks Investment Research downgraded Inovalon from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. ValuEngine downgraded Inovalon from a “hold” rating to a “sell” rating in a report on Wednesday, March 7th. Finally, Wells Fargo reaffirmed a “market perform” rating and set a $14.00 price target (down previously from $16.00) on shares of Inovalon in a research note on Wednesday, February 21st. Three research analysts have rated the stock with a sell rating and four have given a hold rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $12.00.

In other Inovalon news, insider Shauna L. Vernal sold 44,270 shares of Inovalon stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $14.00, for a total value of $619,780.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 48.28% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/somewhat-negative-news-coverage-somewhat-unlikely-to-affect-inovalon-inov-share-price.html.

About Inovalon

Inovalon Holdings, Inc, a technology company, provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models in the healthcare industry. The company's platform enables the assessment and enhancement of clinical and quality outcomes and financial performance.

Insider Buying and Selling by Quarter for Inovalon (NASDAQ:INOV)

Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply